title: Effects of Saiko-ka-ryukotsu-borei-to in patients with hyperlipidemia.
abstract: We measured and compared levels of platelet-derived microparticles (PMPs), monocyte-derived microparticles (MMPs), CD62P on activated platelets, soluble E-selectin (sE-selectin), and anti-oxidized low density lipoprotein (LDL) antibody in hyperlipidemia patients and control subjects. Binding of anti-GPIIb/IIIa and anti-GPIb monoclonal antibodies to platelets was not significantly different between hyperlipidemia patients and controls. However, expression of CD62P on platelets and levels of PMPs were higher for hyperlipidemia patients than in controls, although the difference between groups in CD62P expression was not significant (PMPs: 534 +/- 63 vs. 388 +/- 47, p < 0.05; CD62P: 9.1% +/- 1.45 vs. 7.3% +/- 1.15, N.S.). Although there were no differences in expression of CD36 and CD40 by monocytes between the two groups, levels of MMPs were higher in hyperlipidemia patients than in controls (MMPs: 147 +/- 21 vs. 59 +/- 8, respectively, p < 0.01). Levels of anti-oxidized LDL antibody and sE-selectin were also higher in hyperlipidemia patients. We studied the effects of Saiko-ka-ryukotsu-borei-to on levels of these factors in patients with elevated triglyceride levels. After Saiko-ka-ryukotsu-borei-to treatment, levels of CD62P, PMPs, sE-selectin, and anti-oxidized LDL antibody were reduced significantly. Levels of triglycerides, total cholesterol and MMPs also decreased, but the changes were not significant. These findings suggest that Saiko-ka-ryukotsu-borei-to prevents the development of vascular complications in hyperlipidemia patients.
authors: First Department of Internal Medicine, Kansai Medical University, Moriguchi Osaka, Japan. fwkg4681@mb.infoweb.ne.jp
authors: S
authors: S
authors: Nomura
authors: N
authors: N
authors: Hattori
authors: I
authors: I
authors: Sakakibara
authors: S
authors: S
authors: Fukuhara
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D015415:Biomarkers; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D019040:E-Selectin / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D007564:Japan; D008077:Lipoproteins, LDL / Q000276:immunology / Q000378:metabolism; D008297:Male; D020835:Medicine, Kampo; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D010084:Oxidation-Reduction; D019007:P-Selectin / Q000276:immunology; D008517:Phytotherapy; D010946:Plants, Medicinal; D015539:Platelet Activation / Q000276:immunology; D016896:Treatment Outcome; D014652:Vascular Diseases / Q000517:prevention & control
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D019040:E-Selectin; D008077:Lipoproteins, LDL; D019007:P-Selectin; C095444:saiko-ka-ryukotsu-borei-to